Immunization with recombinant PlpE of ovine Mannheimia haemolytica isolate provides protection against lethal
A Yektaseresht1, Z Hemati2, F Sabet Sarvestani1
1Department of Pathobiology, School of Veterinary Medicine, Shiraz University, Shiraz, Iran.
Background:
Mannheimia haemolytica primarily causes pneumonia leading to heavy morbidity and mortality in domestic livestock world-wide. Recently, outer membrane lipoproteins have emerged as targets for inducing protective immunity against the Pasteurella infection.
Aims:
This study aimed to evaluate recombinant outer membrane lipoprotein E (PlpE) from the ovine M. haemolytica isolate, as a potential vaccine candidate.
Methods:
Recombinant PlpE was constructed using pET26 (b) expression vector in Escherichia coli. Expressed recombinant PlpE was purified and injected subcutaneously to mice. The protection index of the vaccine was evaluated by challenge of mice intraperitoneally.
Results:
Anti-PlpE antibody responses in the immunized mice was significantly increased in comparison with the control group which in turn, provided effective protection when challenged with strain of virulent M. haemolytica.
Conclusion:
Recombinant PlpE from ovine M. haemolytica isolate had the potential to be used as a vaccine candidate against M. haemolytica infection in sheep flocks.
Insights
Recombinant outer membrane lipoprotein E (PlpE) from Mannheimia haemolytica shows potential as a vaccine candidate. Immunization increased antibody responses and provided effective protection against M. haemolytica infection in mice.
Area of Science:
- Veterinary Immunology
- Bacteriology
- Vaccine Development
Background:
- Mannheimia haemolytica causes significant pneumonia, morbidity, and mortality in livestock globally.
- Outer membrane lipoproteins are emerging targets for protective immunity against Pasteurella infections.
Purpose of the Study:
- To evaluate recombinant outer membrane lipoprotein E (PlpE) from an ovine M. haemolytica isolate as a potential vaccine candidate.
Main Methods:
- Recombinant PlpE was constructed in Escherichia coli using the pET26(b) expression vector.
- Purified recombinant PlpE was administered to mice subcutaneously.
- The vaccine's protection index was assessed via intraperitoneal challenge with virulent M. haemolytica.
Main Results:
- Mice immunized with recombinant PlpE showed significantly increased anti-PlpE antibody responses compared to controls.
- Immunized mice demonstrated effective protection when challenged with a virulent M. haemolytica strain.
Conclusions:
- Recombinant PlpE from ovine M. haemolytica is a promising vaccine candidate.
- This could lead to improved control strategies for M. haemolytica infections in sheep flocks.
